Hayakawa H, Shimizu M, Nishida A, Yamawaki S
Department of Psychiatry and Neurosciences, Hiroshima University School of Medicine, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Jun;14(3):179-84.
Two subtypes (alpha 1A and alpha 1B) of alpha 1-adrenoceptors have been defined on the basis of radioligand binding studies with 2-(2,6-dimethoxyphenoxyethyl)-1,4-benzodioxane (WB4101). In contrast, functional studies with blood vessels have proposed another subclassification, where the alpha 1-adrenoceptors can be classified into putative two (alpha 1H and alpha 1L) or three (alpha 1H, alpha 1L and alpha 1N) subtypes. The present study was performed to elucidate the effects of repeated treatment with electroconvulsive shock (ECS) or imipramine on the subtypes of alpha 1-adrenoceptors. The density of the alpha 1H binding sites (including alpha 1A and alpha 1B binding sites) in the frontal cortex was increased by repeated treatment with ECS but decreased by imipramine. These treatments did not change the density of alpha 1L binding sites. These results indicated that repeated treatment with ECS and imipramine had different effects on the alpha 1H binding sites in the rat frontal cortex. In addition, the effects of antipsychotic drugs, antidepressant drugs and calcium channel antagonists on [3H]prazosin binding were studied. The order of inhibition of [3H]prazosin binding was: antipsychotic drugs (1.4-4.2 nM) > antidepressant drugs (69-116 nM) > calcium channel antagonists. The calcium channel antagonists, verapamil (720 nM), diltiazem (4.3 microM) and nicardipine (75 microM) were weakly bound. These results suggested that the antimanic effects of calcium channel antagonists were not associated with inhibition of alpha 1-adrenoceptors.
基于使用2-(2,6-二甲氧基苯氧基乙基)-1,4-苯并二恶烷(WB4101)进行的放射性配体结合研究,已确定了α1-肾上腺素能受体的两种亚型(α1A和α1B)。相比之下,对血管进行的功能研究提出了另一种分类方法,其中α1-肾上腺素能受体可分为假定的两种亚型(α1H和α1L)或三种亚型(α1H、α1L和α1N)。进行本研究以阐明反复电惊厥休克(ECS)或丙咪嗪治疗对α1-肾上腺素能受体亚型的影响。反复ECS治疗可增加额叶皮质中α1H结合位点(包括α1A和α1B结合位点)的密度,但丙咪嗪可使其降低。这些治疗并未改变α1L结合位点的密度。这些结果表明,反复ECS和丙咪嗪治疗对大鼠额叶皮质中的α1H结合位点有不同影响。此外,还研究了抗精神病药物、抗抑郁药物和钙通道拮抗剂对[3H]哌唑嗪结合的影响。抑制[3H]哌唑嗪结合的顺序为:抗精神病药物(1.4 - 4.2 nM)>抗抑郁药物(69 - 116 nM)>钙通道拮抗剂。钙通道拮抗剂维拉帕米(720 nM)、地尔硫卓(4.3 μM)和尼卡地平(75 μM)结合较弱。这些结果表明,钙通道拮抗剂的抗躁狂作用与抑制α1-肾上腺素能受体无关。